New drug approval: Ciltacabtagene autoleucel - in patients with relapsed or refractory multiple myeloma who received 3 or more lines of therapy

被引：0
作者：
Chacon, Aurelia [1 ]
Bobin, Arthur [1 ]
Leleu, Xavier [1 ]
机构：
[1] CHU Poitiers, Serv Oncohematol, 2 Rue Mil,Cs 90577, F-86000 Poitiers, France
来源：
BULLETIN DU CANCER | 2022年 / 109卷 / 10期
关键词：
Multiple myeloma; CAR T; Anti-BCMA;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：993 / 995
页数：3
相关论文
共 50 条
  • [41] Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
    Yalniz, Fevzi Firat
    Akkoc, Nihan
    Salihoglu, Ayse
    Ar, M. Cem
    Ongoren, Seniz
    Eskazan, A. Emre
    Soysal, Teoman
    Aydin, Yildiz
    TURKISH JOURNAL OF HEMATOLOGY, 2017, 34 (03) : 233 - 238
  • [42] Evaluation of Ixazomib Relative Dose Intensity for IRd Therapy in Elderly Patients with Relapsed or Refractory Multiple Myeloma: A Preliminary Study
    Kanda, Tomoe
    Kimura, Michio
    Sugiyama, Tomoki
    Hirose, Tatsuya
    Takenaka, Shoya
    Usami, Eiseki
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2025, 145 (03): : 257 - 264
  • [43] Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis
    Bringhen, Sara
    Pour, Ludek
    Vorobyev, Vladimir
    Vural, Filiz
    Warzocha, Krzysztof
    Benboubker, Lotfi
    Koh, Youngil
    Maisnar, Vladimir
    Karlin, Lionel
    Pavic, Michel
    Campana, Frank
    Le Guennec, Solenn
    Menas, Fatima
    van de Velde, Helgi
    Richardson, Paul G.
    LEUKEMIA RESEARCH, 2021, 104
  • [44] Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
    Grzasko, Norbert
    Charlinski, Grzegorz
    Morawska, Marta
    Kicinski, Pawel
    Waszczuk-Gajda, Anna
    Drozd-Sokolowska, Joanna
    Subocz, Edyta
    Blonska, Danuta
    Razny, Malgorzata
    Druzd-Sitek, Agnieszka
    Holojda, Jadwiga
    Swiderska, Alina
    Usnarska-Zubkiewicz, Lidia
    Masternak, Anna
    Giannopoulos, Krzysztof
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
  • [45] Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy
    Anagnostopoulos, A
    Aleman, A
    Yang, Y
    Donato, M
    Weber, D
    Champlin, R
    Smith, T
    Alexanian, R
    Giralt, S
    BONE MARROW TRANSPLANTATION, 2004, 33 (06) : 623 - 628
  • [46] Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy
    A Anagnostopoulos
    A Aleman
    Y Yang
    M Donato
    D Weber
    R Champlin
    T Smith
    R Alexanian
    S Giralt
    Bone Marrow Transplantation, 2004, 33 : 623 - 628
  • [47] Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed–refractory multiple myeloma
    Massimo Offidani
    Laura Corvatta
    Claudia Polloni
    Silvia Gentili
    Anna Mele
    Rita Rizzi
    Massimo Catarini
    Patrizia Caraffa
    Arduino Samori
    Nicola Blasi
    Mario Ferranti
    Lara Malerba
    Marino Brunori
    Pietro Leoni
    Annals of Hematology, 2011, 90 : 1449 - 1456
  • [48] A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: β2-microglobulin associated with time to progression
    Hiroto Ohguchi
    Tomohiro Sugawara
    Izumi Ishikawa
    Mitsutaka Okuda
    Yasuo Tomiya
    Joji Yamamoto
    Yasushi Onishi
    Minami Fujiwara Yamada
    Kenichi Ishizawa
    Junichi Kameoka
    Hideo Harigae
    International Journal of Hematology, 2009, 89 : 342 - 347
  • [49] A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: β2-microglobulin associated with time to progression
    Ohguchi, Hiroto
    Sugawara, Tomohiro
    Ishikawa, Izumi
    Okuda, Mitsutaka
    Tomiya, Yasuo
    Yamamoto, Joji
    Onishi, Yasushi
    Yamada, Minami Fujiwara
    Ishizawa, Kenichi
    Kameoka, Junichi
    Harigae, Hideo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (03) : 342 - 347
  • [50] Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
    Berenson, James R.
    Yellin, Ori
    Bessudo, Alberto
    Boccia, Ralph V.
    Noga, Stephen J.
    Gravenor, Donald S.
    Patel-Donnelly, Dipti
    Siegel, Robert S.
    Kewalramani, Tarun
    Gorak, Edward J.
    Nassir, Youram
    Swift, Regina A.
    Mayo, Debra
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (03) : 321 - 330
12345